Neola Medical AB

Equities

GPXMED

SE0014829255

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-28 EDT			5-day change	1st Jan Change
2.2 ^SEK	+1.85%		+2.80%	+12.82%

05-22	Neola Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-14	Neola Medical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Neola Medical's CEO Announces Key Achievements in the Summer 2024 Investor Letter

June 18, 2024 at 02:50 am

Neola Medical has reached several critical milestones aligned with its business strategy, aimed at market approval by the FDA. A Human Factors Validation Study of the company’s medical device for lung monitoring, Neola®, was successfully concluded with neonatal nurses in the USA, and will lay a foundation for the upcoming market grant application to FDA. Additionally, Neola® obtained a CB certificate according to high International standards, meeting partial regulatory requirements for market approval in the USA.

“These achievements lay a strong foundation for our upcoming FDA application for market approval in the USA. We now advance to the clinical validation phase and intensify planning for the clinical study in the USA on preterm born infants.”, says CEO Hanna Sjöström.

Read more about the latest news in the investor letter summer 2024, attached to this press release and available on the company’s website www.neolamedical.se

About Neola Medical
Neola Medical AB (publ) develops revolutionizing medical technology device for non-invasive continuous lung monitoring and real-time alerts of life-threatening lung complications of preterm born infants. Immediate detection of complications provides the possibility of early treatment, improved health care and healthier lives for preterm born infants. The patented cutting-edge technology is developed at Lund University in Sweden and based on a spectroscopic method that measures lung volume changes and oxygen gas concentration. Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Latest news about Neola Medical AB

Neola Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-22	CI
Neola Medical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-14	CI
Neola Medical Receives New Patent Approval in Europe for the Neola Lung Monitoring System	12-20	CI
Neola Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Neola Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
Neola Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
Neola Medical AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-14	CI
Neola Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-14	CI
Neola Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Neola Medical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
GPX Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-19	CI
GPX Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-15	CI
GPX Medical AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-15	CI
GPX Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-09	CI
Gpx Medical AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-17	CI
Gpx Medical AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-20	CI
BioImpact Pty Ltd Secures Exclusive Distribution Rights for NEOLA® from GPX Medical	21-02-21	CI
Cardeon Futuring Finance AB acquired an unknown minority stake in GPX Medical AB (OM:GPXMED) from Norsk Elektro Optikk AS.	21-02-11	CI
GPX Medical AB has completed an IPO in the amount of SEK 22.5 million.	20-10-02	CI
GPX Medical AB has filed an IPO in the amount of SEK 22.5 million.	20-09-04	CI
GPX Medical Recruits Hanna Sjöström as New CEO from January 28, 2019	19-01-22	CI
GPX Medical AB announced that it has received SEK 3 million in funding from Gasporox AB, Norsk Elektro Optikk A/S.	17-02-16	CI

Chart Neola Medical AB

Duration

Period

More charts

Company Profile

Neola Medical AB, formerly GPX Medical AB is a Sweden-based company that is involved in development of medical instruments. The Company's business concept is to commercialize the Company's medical technology product for continuous lung monitoring based on the patented GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical's technology equipment aims for continuous monitoring of the lungs of premature babies. The primary purpose of Neola Medical is to support neonatal intensive care with NEOLA, a medical device that can offer continuous lung monitoring and real-time alerts about life-threatening complications using new technology that measures lung volume changes and oxygen concentration.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Medical Equipment

	1st Jan change	Capi.
NEOLA MEDICAL AB	+12.82%	14.26M
SHOCKWAVE MEDICAL	+75.67%	12.57B
MASIMO CORPORATION	+7.45%	6.98B
PENUMBRA, INC.	-28.45%	6.78B
GETINGE AB	-19.73%	4.59B
APT MEDICAL INC.	+17.40%	4.15B
ASAHI INTECC CO., LTD.	-21.37%	3.83B
INARI MEDICAL, INC.	-25.83%	2.73B
SKAN GROUP AG	-1.24%	2B
NOVOCURE LIMITED	+14.74%	1.9B

Medical Equipment